Karran Emma L, McAuley James H, Traeger Adrian C, Hillier Susan L, Grabherr Luzia, Russek Leslie N, Moseley G Lorimer
Sansom Institute for Health Research, University of South Australia, GPO Box 2471, Adelaide, South Australia, 5001, Australia.
Neuroscience Research Australia, Barker Street, Randwick, Sydney, New South Wales, 2031, Australia.
BMC Med. 2017 Jan 19;15(1):13. doi: 10.1186/s12916-016-0774-4.
Delivering efficient and effective healthcare is crucial for a condition as burdensome as low back pain (LBP). Stratified care strategies may be worthwhile, but rely on early and accurate patient screening using a valid and reliable instrument. The purpose of this study was to evaluate the performance of LBP screening instruments for determining risk of poor outcome in adults with LBP of less than 3 months duration.
Medline, Embase, CINAHL, PsycINFO, PEDro, Web of Science, SciVerse SCOPUS, and Cochrane Central Register of Controlled Trials were searched from June 2014 to March 2016. Prospective cohort studies involving patients with acute and subacute LBP were included. Studies administered a prognostic screening instrument at inception and reported outcomes at least 12 weeks after screening. Two independent reviewers extracted relevant data using a standardised spreadsheet. We defined poor outcome for pain to be ≥ 3 on an 11-point numeric rating scale and poor outcome for disability to be scores of ≥ 30% disabled (on the study authors' chosen disability outcome measure).
We identified 18 eligible studies investigating seven instruments. Five studies investigated the STarT Back Tool: performance for discriminating pain outcomes at follow-up was 'non-informative' (pooled AUC = 0.59 (0.55-0.63), n = 1153) and 'acceptable' for discriminating disability outcomes (pooled AUC = 0.74 (0.66-0.82), n = 821). Seven studies investigated the Orebro Musculoskeletal Pain Screening Questionnaire: performance was 'poor' for discriminating pain outcomes (pooled AUC = 0.69 (0.62-0.76), n = 360), 'acceptable' for disability outcomes (pooled AUC = 0.75 (0.69-0.82), n = 512), and 'excellent' for absenteeism outcomes (pooled AUC = 0.83 (0.75-0.90), n = 243). Two studies investigated the Vermont Disability Prediction Questionnaire and four further instruments were investigated in single studies only.
LBP screening instruments administered in primary care perform poorly at assigning higher risk scores to individuals who develop chronic pain than to those who do not. Risks of a poor disability outcome and prolonged absenteeism are likely to be estimated with greater accuracy. It is important that clinicians who use screening tools to obtain prognostic information consider the potential for misclassification of patient risk and its consequences for care decisions based on screening. However, it needs to be acknowledged that the outcomes on which we evaluated these screening instruments in some cases had a different threshold, outcome, and time period than those they were designed to predict.
PROSPERO international prospective register of systematic reviews registration number CRD42015015778 .
对于像腰痛(LBP)这样负担沉重的疾病,提供高效且有效的医疗保健至关重要。分层护理策略可能是值得的,但依赖于使用有效且可靠的工具进行早期和准确的患者筛查。本研究的目的是评估LBP筛查工具在确定病程少于3个月的成年LBP患者不良结局风险方面的性能。
检索了2014年6月至2016年3月期间的Medline、Embase、CINAHL、PsycINFO、PEDro、科学引文索引、SciVerse SCOPUS和Cochrane对照试验中央注册库。纳入了涉及急性和亚急性LBP患者的前瞻性队列研究。研究在开始时使用了一种预后筛查工具,并在筛查后至少12周报告结局。两名独立的评审员使用标准化电子表格提取相关数据。我们将疼痛的不良结局定义为在11点数字评分量表上≥3分,将残疾的不良结局定义为残疾得分≥30%(根据研究作者选择的残疾结局测量方法)。
我们确定了18项符合条件的研究,这些研究调查了7种工具。5项研究调查了STarT Back工具:其在区分随访时疼痛结局方面的性能为“无信息价值”(合并AUC = 0.59(0.55 - 0.63),n = 1153),在区分残疾结局方面为“可接受”(合并AUC = 0.74(0.66 - 0.82),n = 821)。7项研究调查了厄勒布鲁肌肉骨骼疼痛筛查问卷:其在区分疼痛结局方面的性能为“差”(合并AUC = 0.69(0.62 - 0.76),n = 360),在区分残疾结局方面为“可接受”(合并AUC = 0.75(0.69 - 0.82),n = 512),在区分旷工结局方面为“优秀”(合并AUC = 0.83(0.75 - 0.90),n = 243)。2项研究调查了佛蒙特残疾预测问卷,另外4种工具仅在单项研究中被调查。
在初级保健中使用的LBP筛查工具,对于那些发展为慢性疼痛的个体,在赋予其比未发展为慢性疼痛个体更高风险评分方面表现不佳。残疾不良结局和旷工时间延长的风险可能会被更准确地估计。使用筛查工具获取预后信息的临床医生必须考虑患者风险误分类的可能性及其对基于筛查的护理决策的影响,这一点很重要。然而,需要承认的是,我们在某些情况下评估这些筛查工具所依据的结局,在阈值、结局和时间段方面与它们设计用于预测的情况有所不同。
国际前瞻性系统评价注册库PROSPERO注册号CRD42015015778 。